ALK inhibitors have followed a rapid trajectory from bench to bedside, taking over from chemotherapy as standard frontline treatment for patients with advanced non– small-cell lung cancer with ALK gene rearrangements.
Original Article: Bounty of Novel Drugs Ushers In New Era for ALK-Positive NSCLC
NEXT ARTICLE